COMPANY

CoRegen

Keywords: oncology cancer protein therapeutics HER2-negative Breast Cancer HR-positive TNBC - Triple-Negative Breast Cancer Prostate Cancer CRG-150

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $13.5M (Form D filed Feb 26, 2026). SEC Form D 0002012886-26-000003 (Feb 26, 2026)
Evidence (1 event)
- Feb 26, 2026 · SEC Form D 0002012886-26-000003
  Name of Issuer: CoRegen, Inc.; CIK: 2012886; Address: Houston, TX; Submission type: D; Filing date: 2026-02-26; Industry Group: Biotechnology; Date of First Sale: 2025-10-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 13500000; Total Amount Sold: 13500000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

2026-11 Trial start Phase 1/Phase 2: Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies source ↗
Jul 9, 2025 Raise Private equity round: $93M (total, as published), announced Jul 9, 2025. Source: company release on GlobeNewswire. source ↗

2029-06 (ESTIMATED) · Phase 1/Phase 2 · Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies · NCT07730125

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $93.0M. Last 2 years.

Jul 9, 2025 Private equity round: $93M (total, as published), announced Jul 9, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07730125	Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies	Phase 1/Phase 2	Not yet recruiting	2026-11	2029-06 (estimated)